Want to see PMN full AI Analyst Report?
Top Page
ProMIS Neurosciences
(NASDAQ:PMN)
Select Model
Select Model
Rating:54Neutral
Price Target:
$15.00
▲(22.95% Upside)
Action:Reiterated
Date:07/29/26
The score is held back primarily by weak financial performance—no revenue, heavy losses, and persistent cash burn—despite a low-debt balance sheet. Technicals are supportive with the stock above key moving averages, and corporate news is constructive on interim trial safety/biomarker signals, but valuation signals are limited due to a negative P/E and no dividend data.
Positive Factors
Clinical progress: PMN310 interim safety & biomarkers
Blinded interim data showing favorable safety across genotypes, no ARIA‑E, and early biomarker reductions materially de‑risks PMN310's clinical profile. Over 2–6 months this strengthens the program's chance to reach unblinded efficacy readouts and attracts partners, underwriting longer‑term development and partnership optionality.
Negative Factors
Pre-revenue with heavy cash burn
As a pre‑revenue biotech, PMN runs sizable recurring losses and negative operating/free cash flow, necessitating external capital. Over months this cash burn constrains runway, raises execution risk for trials, and increases the likelihood of dilutive financings if non‑dilutive partnerships or milestone inflows do not materialize.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical progress: PMN310 interim safety & biomarkers
Blinded interim data showing favorable safety across genotypes, no ARIA‑E, and early biomarker reductions materially de‑risks PMN310's clinical profile. Over 2–6 months this strengthens the program's chance to reach unblinded efficacy readouts and attracts partners, underwriting longer‑term development and partnership optionality.
Read all positive factors
ProMIS Neurosciences (PMN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$123.04M
Dividend YieldN/A
Average Volume (3M)75.89K
Price to Earnings (P/E)―
Beta (1Y)0.17
Revenue GrowthN/A
EPS Growth-1753.64%
CountryUS
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-23.59
Shares Outstanding8,967,693
10 Day Avg. Volume133,844
30 Day Avg. Volume75,892
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-9.53K
Price to Sales (P/S)0.00
P/FCF Ratio-426.74
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$35.96Price Target Upside194.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-5.28
Revenue Forecast (FY)N/A
ProMIS Neurosciences Business Overview & Revenue Model
Company Description
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple syst...
How the Company Makes Money
PMN is a clinical-stage/pre-commercial biotechnology company; specific, recurring product revenue is null. Its primary way of generating cash is through financing activities common to development-stage biopharma (e.g., issuing equity and related f...
ProMIS Neurosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ― |
| Gross Profit | -9.36M | 0.00 | 0.00 | -10.44M | 0.00 | ― |
| EBITDA | -41.02M | -39.72M | 2.86M | -17.81M | -17.77M | -9.33M |
| Net Income | -40.62M | -39.72M | 2.78M | -17.51M | -18.06M | ― |
Balance Sheet | ||||||
| Total Assets | 67.41M | 9.18M | 18.91M | 13.62M | 9.38M | 22.44M |
| Cash, Cash Equivalents and Short-Term Investments | 63.85M | 6.15M | 13.32M | 12.63M | 8.01M | 21.48M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.94M |
| Total Liabilities | 6.69M | 10.44M | 2.42M | 9.87M | 11.20M | 15.28M |
| Stockholders Equity | 60.72M | -1.26M | 16.49M | 3.75M | -1.82M | 7.16M |
Cash Flow | ||||||
| Free Cash Flow | -35.47M | -28.12B | -27.18M | -10.84M | -17.04M | -9.45M |
| Operating Cash Flow | -35.47M | -28.12B | -27.18M | -10.84M | -17.03M | -9.44M |
| Investing Cash Flow | -703.00 | -702.00K | -693.00 | -1.35K | -1.98K | 95.93K |
| Financing Cash Flow | 91.07M | 20.94B | 27.88M | 17.75M | 6.49M | 25.63M |
ProMIS Neurosciences Technical Analysis
Positive
12.20
Price Trends
12.02
Positive
12.41
Positive
12.00
Positive
Market Momentum
0.46
Positive
51.67
Neutral
42.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMN, the sentiment is Positive. The current price of 12.2 is below the 20-day moving average (MA) of 13.81, above the 50-day MA of 12.02, and above the 200-day MA of 12.00, indicating a neutral trend. The MACD of 0.46 indicates Positive momentum. The RSI at 51.67 is Neutral, neither overbought nor oversold. The STOCH value of 42.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PMN.
ProMIS Neurosciences Risk Analysis
ProMIS Neurosciences disclosed 80 risk factors in its most recent earnings report. ProMIS Neurosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ProMIS Neurosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $123.04M | -0.58 | -237.99% | ― | ― | -1753.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $74.45M | -1.02 | -318.08% | ― | ― | 20.55% | |
44 Neutral | $185.42M | -0.14 | 359.80% | ― | ― | -3629.03% | |
44 Neutral | $8.17M | -1.93 | -43.95% | ― | 11.90% | 43.46% | |
41 Neutral | $16.44M | -1.04 | 1070.23% | ― | ― | ― |
* Healthcare Sector Average
PMN
ProMIS Neurosciences
13.48
-1.27
-8.60%
NERV
Minerva Neurosciences
4.35
2.55
141.00%
IMRN
Immuron
1.10
-0.54
-32.93%
ANVS
Annovis Bio
1.87
-0.80
-29.96%
NRSN
Neurosense Therapeutics Ltd.
0.54
-0.80
-59.63%
ProMIS Neurosciences Corporate Events
Business Operations and StrategyProduct-Related Announcements
ProMIS Reports Positive Interim PMN310 Alzheimer’s Trial Data
Positive
Jul 28, 2026
On July 28, 2026, ProMIS Neurosciences reported blinded six‑month interim data from PRECISE‑AD, its Phase 1b trial of lead antibody PMN310 in early Alzheimer’s patients, showing a favorable safety profile in 136 participants with...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
ProMIS Neurosciences shareholders approve directors and incentive plan
Positive
May 20, 2026
On May 20, 2026, ProMIS Neurosciences held its Annual Meeting, at which shareholders representing approximately 53.1% of outstanding common shares were present or represented by proxy. Investors elected seven directors to serve until the 2027 annu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.